BRAF and non-Hodgkin lymphoma: Since RAS–RAF–MEK–ERK–MAP kinase pathway is activated by protein kinase, therapies that target this signalling pathway would therefore be very valuable in treating tumours that have activating mutations of BRAF. In this respect, the present study may provide the possibility of therapy targeting mutated BRAF in NHL.